Skip to content

Cancer Screening Smoking Cessation AND Respiratory Assessment

Lung Cancer Screening Pilot Programme: Cancer Screening Smoking Cessation AND Respiratory Assessment

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06157957
Acronym
CASSANDRA
Enrollment
40000
Registered
2023-12-06
Start date
2023-12-31
Completion date
2028-12-31
Last updated
2023-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Protection Against Malignant Lung Neoplasm (Diagnosis)

Keywords

lung cancer, tobacco cessation, respiratory assessment

Brief summary

The CASSANDRA project (Cancer Screening, Smoking Cessation, AND Respiratory Assessment) is a project led by SEPAR whose main coordinators are Dr. Luis Seijo, a pulmonologist at the Clínica Universitaria de Navarra, and Dr. Juan Carlos Trujillo-Reyes, a thoracic surgeon at the Hospital de la Santa Creu I Sant Pau and Coordinator of the Thoracic Oncology Area, in addition to the collaboration of a large number of professionals with expertise in lung cancer screening. Despite its proven efficacy, Spain does not yet have a unified lung cancer screening protocol. The aim of the CASSANDRA project is to initiate a national screening program that can join forces with existing smoking cessation programs in Spain, which have proven to be insufficient in reducing the number of people affected by lung cancer. CASSANDRA aims to analyze the feasibility of implementing a lung cancer screening program in Spain implemented in the public health system and carry out a cost-effectiveness analysis

Detailed description

CASSANDRA aims to be the first lung cancer screening pilot project in Spain. A project to assess the feasibility of implementation as well as to look for models that allow a better selection of the cases to be screened.

Interventions

DIAGNOSTIC_TESTLung cancer screening with low dose CT scan

Low dose CT scan in active smokers or ex-smokers with an age between 50 and 75 years old

Sponsors

Sociedad Española de Neumología y Cirugía Torácica
CollaboratorOTHER
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 50-75 years active smoker with cumulative dose of \>20 packets/year * Age 50-75 years ex-smoker less than 15 years old with cumulative dose of \> 20 packets/year

Exclusion criteria

* Pre-existing or new-onset comorbidities that, in the opinion of the coordinator, prevent surgical resection if lung cancer is found on low dose computed tomography (LDCT) scan, for example, severe chronic obstructive pulmonary disease (COPD) with forced expiratory volume at one second (FEV1) \< 30%. * Inability to sign the informed consent or collaborate with the CT scan. * Performing a chest CT for any reason in the previous year or planned CT for any reason in the next 3 months. * Subjects with a history of any cancer (except non-melanoma skin cancer) in the 5 years prior to inclusion in the screening program.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of lung cancer in early stage in a high risk population during a lung cancer screening programme. We measure this outcome depending on the CT results.0 years until 5 yearsLung cancer screening
The number of patients who quit smoking during a lung cancer screening program. We will measure this parameter by recording smoking cessation during the 5 years.0 years until 5 yearsTobacco Cessation
The number of patients who present other diseases associated with smoking such as emphysema, COPD or coronary pathology. We will measure this parameter by means of spirometry and CT scan.0 years until 5 yearsRespiratory assessment

Contacts

Primary ContactJuan Carlos Trujillo Reyes, MD/PHD
jtrujillo@santpau.cat0034654032813
Backup ContactLuis Seijo Maceiras, MD/PHD
lseijo@unav.es

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026